. 2003 Oct;185(20):6057–6066. doi: 10.1128/JB.185.20.6057-6066.2003

TABLE 2.

Primers used in this study

Primer^a	Sequence	Description^b
Cps2-A4 (+)	GGTCGCAACCAACAAAAGG	cps2A^2584-2602
Cps2-A5 (−)	CCATCACATCCTGTATAGC	cps2A^2896-2878
Cps2-B4 (+)	GCTCAGGAACTTTTTATAGAC	cps2B^3584-3604
Cps2-C1 (−)	GTCAGTTGGTACAGTCACTTG	cps2C^4005-3985
Cps2-D1 (−)	CCGACAGGAGCTGTATCTAC	cps2D^4820-4801
Cps2-D3 (+)	CTCACAGGCAAAATTGGATTTTG	cps2D^4368-4390
Cps2-G1 (+)	GGTCTTTCTGACAACGAGTATC	cps2G^9078-9089
Cps2-I3 (−)	CCACCTGAATTTGTCCCAATAAC	cps2I^11907-11884
LDH-F (+)	GTCGGTGATGGTGCTGTAGGTTCATC	ldh^164-189
LDH-R (−)	GTCGATGTTAGCGTGTGACCAAACAG	ldh^710-687

Forward and reverse primers are represented by plus (+) and minus (−), respectively.

Numbers in superscript represent the positions of the start and finish of the homologous region of the primer when compared to the published type 2 capsule sequence (GenBank accession no. AF026471) (36) or the published TIGR4 ldh sequence (GenBank accession no. AE007422) (58).